The Current Ratio as of September 2024 (TTM) for Dyadic International, Inc. (DYAI) is 5.39

According to Dyadic International, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 5.39. This represents a change of 3.89% compared to the average of 5.19 of the last 4 quarters.

Dyadic International, Inc. (DYAI) Historical Current Ratio (quarterly & annually)

How has DYAI Current Ratio performed in the past?

The mean historical Current Ratio of Dyadic International, Inc. over the last ten years is 25.68. The current 5.39 Current Ratio has changed 2.00% with respect to the historical average. Over the past ten years (40 quarters), DYAI's Current Ratio was at its highest in in the June 2018 quarter at 97.72. The Current Ratio was at its lowest in in the June 2015 quarter at 0.73.

Dyadic International, Inc. (DYAI) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Dyadic International, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Dyadic International, Inc. (DYAI) Average Current Ratio

How has DYAI Current Ratio performed in the past?

The current Current Ratio of Dyadic International, Inc. (DYAI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

Dyadic International, Inc. (DYAI) Current Ratio vs. Peers

How is DYAI’s Current Ratio compared to its peers?

Dyadic International, Inc.’s Current Ratio is less than Werewolf Therapeutics, Inc. (12.13), less than Edgewise Therapeutics, Inc. (30.24), greater than Decibel Therapeutics, Inc. (3.03), less than Celcuity Inc. (14.95), greater than C4 Therapeutics, Inc. (5.09), greater than Anebulo Pharmaceuticals, Inc. (5.32), less than PMV Pharmaceuticals, Inc. (19.22), less than AN2 Therapeutics, Inc. (10.61), less than Eliem Therapeutics, Inc. (60.41), greater than HCW Biologics Inc. (0.10), less than Molecular Partners AG (14.58), less than MediciNova, Inc. (18.24), greater than Champions Oncology, Inc. (0.63), less than Cyteir Therapeutics, Inc. (21.89), greater than Forte Biosciences, Inc. (2.82), less than DiaMedica Therapeutics Inc. (17.82), greater than Kineta, Inc. (0.14), greater than Kintara Therapeutics, Inc. (5.04),

Build a custom stock screener for Dyadic International, Inc. (DYAI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Dyadic International, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Dyadic International, Inc. (DYAI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Dyadic International, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.